Tadalafil Tablet, Film Coated
Product Images NDC 60290-030

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 13 technical images submitted to the FDA as part of the official labeling for Tadalafil (NDC 60290-030). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Umedica Laboratories Usa Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

"image Description" (Tadalafil 10 mg 30s Bottle Label)

"image Description" (Tadalafil 10 mg 30s Bottle Label)
This text provides information about a medication with 10 mg of Tadalafil USP. It includes directions on storage at room temperature, a warning to keep out of reach of children, and a reminder to not split tablets. The package is child-resistant, and the dosage instructions are detailed in accompanying literature. Patient information can be found online. It also mentions the manufacturer and distributor details. The text includes a website link for more information.*
FDA Label Image

"image Description" (Tadalafil 20 mg 30s Bottle Label)

"image Description" (Tadalafil 20 mg 30s Bottle Label)
Each tablet contains 20 mg of Tadalafil USP. The package is child-resistant and should be stored at 25°C (77°F) with excursions permitted between 15° to 30°C (59° to 86°F). Adequate precautions should be taken to keep the tablets out of reach of children and they should be dispensed in a tight container. The usual dosage information can be found in accompanying literature. Patient information is available online at "umedicalabsusa.com". Tablets should not be split and the entire dose should be taken. This is a prescription-only medication distributed by Umedica Laboratories USA Inc. with manufacturing done by Umedica Laboratories P, Ltd. in India. Note the important information as indicated in the text, such as indicative markings on the tablets, the National Drug Code (NDC), and the expiration and lot details.*
FDA Label Image

"image Description" (Tadalafil 2pt5 mg 1000s Bottle Label)

"image Description" (Tadalafil 2pt5 mg 1000s Bottle Label)
Each tablet contains 2.5 mg of Tadalafil USP. The recommended storage temperature is between 15°C to 30°C (59°F to 86°F). This medication should be kept out of reach of children and dispensed in a tight container. The tablets are for once daily use and should not be split. Detailed patient information is available on the provided website. The product is manufactured in India and distributed by Umedica Laboratories USA Inc. Additional information like NDC, manufacturing license number, and contact details are also provided.*
FDA Label Image

"image Description" (Tadalafil 5 mg 30s Bottle Label)

"image Description" (Tadalafil 5 mg 30s Bottle Label)
This text contains information about a tablet that includes 5 mg of Tadalafil USP manufactured and distributed from India. The tablet is child-resistant and should be stored between 15° to 30°. The product is from Umedica Laboratories and contains 30 tablets per package. The text also provides a link for more information.*
FDA Label Image

"image Description" (Tadalafil Figure 1)

FDA Label Image

"image Description" (Tadalafil Figure 2)

"image Description" (Tadalafil Figure 2)
This text appears to be a table showing the standing and supine systolic blood pressure (BP in mmHg) at different time points after taking Tadalafil 20 mg & doxazosin 8 mg compared to Placebo & doxazosin 8 mg. The table includes results at different time points up to 24 hours post-dose.*
FDA Label Image

"image Description" (Tadalafil Figure 3)

"image Description" (Tadalafil Figure 3)
This is a table displaying different treatment regimens involving the administration of tadalafil and doxazosin at different times. Systolic blood pressure (measured in mmHg) is likely being monitored at specific intervals to analyze the effects of these medications. This information can be used to assess the impact of these drugs on blood pressure control.*
FDA Label Image

"image Description" (Tadalafil Figure 4)

"image Description" (Tadalafil Figure 4)
This text displays a chart showing the concentration of plasma Tadalafil in micrograms per liter over time. It compares the levels after a single 20mg dose, a single 5mg dose, and once-daily 5mg doses for 5 consecutive days. The graph indicates the highest concentration with the single 20mg dose and the lowest with the once-daily 5mg dose.*
FDA Label Image

"image Description" (Tadalafil Figure 5)

"image Description" (Tadalafil Figure 5)
This text is not-readable.*
FDA Label Image

"image Description" (Tadalafil Figure 6)

"image Description" (Tadalafil Figure 6)
The text provides information about the change from baseline in IPSS Total Score for Tadalafil Tablets 5 mg compared to Placebo over a duration of treatment in weeks. The results are statistically significant with a P-value of less than 0.01.*
FDA Label Image

"image Description" (Tadalafil Figure 7)

"image Description" (Tadalafil Figure 7)
This is a clinical study evaluating the LS mean change from baseline at different weeks of therapy with Tadalafil and Finasteride compared to Placebo/Finasteride. The data shows the least-squares treatment difference between the groups at each time point, with significant difference observed at various time intervals. The study suggests that combination therapy with Tadalafil and Finasteride may lead to greater improvements compared to Placebo/Finasteride in the given context.*
FDA Label Image

"image Description" (Tadalafil Figure 8)

FDA Label Image

"image Description" (Tadalafil Structure)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.